litlas
Log inCreate account

Jay S. Skyler

Active 1978–2026

95
Papers
19,540
Citations
71
h-index
92
i10-index

Citations

Citations per year for Jay S. Skyler1979: 2 citations1981: 1 citations1982: 6 citations1983: 4 citations1984: 5 citations1985: 1 citations1986: 6 citations1987: 11 citations1988: 7 citations1989: 14 citations1990: 9 citations1991: 17 citations1992: 9 citations1993: 11 citations1994: 11 citations1995: 11 citations1996: 9 citations1997: 17 citations1998: 15 citations1999: 11 citations2000: 14 citations2001: 36 citations2002: 45 citations2003: 44 citations2004: 60 citations2005: 59 citations2006: 52 citations2007: 68 citations2008: 73 citations2009: 65 citations2010: 99 citations2011: 79 citations2012: 109 citations2013: 150 citations2014: 120 citations2015: 149 citations2016: 117 citations2017: 131 citations2018: 134 citations2019: 506 citations2020: 710 citations2021: 696 citations2022: 548 citations2023: 499 citations2024: 780 citations2025: 481 citations2026: 8 citations1980: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,933 citing papers, 27.2% of this breakdownUnited Kingdom: 641 citing papers, 9% of this breakdownChina: 420 citing papers, 5.9% of this breakdownItaly: 360 citing papers, 5.1% of this breakdownGermany: 347 citing papers, 4.9% of this breakdownCanada: 299 citing papers, 4.2% of this breakdownAustralia: 259 citing papers, 3.7% of this breakdownSweden: 214 citing papers, 3% of this breakdownIndia: 164 citing papers, 2.3% of this breakdownDenmark: 160 citing papers, 2.3% of this breakdownFrance: 155 citing papers, 2.2% of this breakdownNetherlands: 145 citing papers, 2% of this breakdown
0%27.2%Other 28.2%

Institutions

Fields

  • Medicine59.1%
  • Biochemistry, Genetics and Molecular Biology30%
  • Immunology and Microbiology3.2%
  • Nursing1.9%
  • Health Professions1.4%
  • Neuroscience0.8%
  • Other3.6%

Topics

  • Diabetes and associated disorders12.6%
  • Diabetes Management and Research12.5%
  • Pancreatic function and diabetes10.8%
  • Diabetes Treatment and Management5.3%
  • COVID-19 Clinical Research Studies2.5%
  • Diabetes, Cardiovascular Risks, and Lipoproteins2.3%
  • Other54%

Coauthors

All papers

Open in search
  1. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Authors: Kevan C. Herold, Brian N. Bundy, S. Alice Long, Jeffrey A. Bluestone, Linda A. DiMeglio, Matthew J. Dufort, Stephen E. Gitelman, Peter A. Gottlieb, Jeffrey P. Krischer, Peter S. Linsley, Jennifer B. Marks, Wayne D. Moore, Antoinette Moran, Henry Rodriguez, William E. Russell, Desmond Schatz, Jay S. Skyler, Eva Tsalikian, Diane K. Wherrett, Anette-Gabriele Ziegler, Carla J. Greenbaum - New England Journal of Medicine 2019 cited by 1,112

  2. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

    Authors: Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jeffrey P. Krischer, Åke Lernmark, Robert E. Ratner, Marian Rewers, Desmond Schatz, Jay S. Skyler, Jay M. Sosenko, Anette‐G. Ziegler - Diabetes Care 2015 cited by 1,148

  3. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    Authors: Richard I. G. Holt, J. Hans DeVries, Amy Hess-Fischl, Irl B. Hirsch, M. Sue Kirkman, Tomasz Klupa, Barbara Ludwig, Kirsten Nørgaard, Jeremy Pettus, Éric Renard, Jay S. Skyler, Frank J. Snoek, Ruth S. Weinstock, Anne L. Peters - Diabetes Care 2021 cited by 658

  4. Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

    Authors: Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf, Dorothy J. Becker, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Jennifer B. Marks, Paula McGee, Antoinette Moran, Philip Raskin, Henry Rodriguez, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, John M. Lachin, Jay S. Skyler - New England Journal of Medicine 2009 cited by 1,073

  5. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

    Authors: Jay S. Skyler, George L. Bakris, Ezio Bonifacio, Tamara Darsow, Robert H. Eckel, Leif Groop, Per‐Henrik Groop, Yehuda Handelsman, Richard A. Insel, Chantal Mathieu, Allison T. McElvaine, Jerry P. Palmer, Alberto Pugliese, Desmond Schatz, Jay M. Sosenko, John Wilding, Robert E. Ratner - Diabetes 2016 cited by 824

  6. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

    Authors: Tihamer Orban, Brian N. Bundy, Dorothy J. Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Jennifer B. Marks, Roshanak Monzavi, Antoinette Moran, Philip Raskin, Henry Rodriguez, William E. Russell, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler - The Lancet 2011 cited by 601

  7. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

    Authors: Julio Rosenstock, Jan Marquard, Lori M. Laffel, Dietmar Neubacher, Stefan Kaspers, David Z.I. Cherney, Bernard Zinman, Jay S. Skyler, Jyothis T. George, Nima Soleymanlou, Bruce A. Perkins - Diabetes Care 2018 cited by 357

  8. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

    Authors: William E. Russell, Brian N. Bundy, Mark S. Anderson, Laura A. Cooney, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Michael J. Haller, Jeffrey P. Krischer, Ingrid Libman, Peter S. Linsley, S. Alice Long, Sandra Lord, Daniel J. Moore, Wayne V. Moore, Antoinette Moran, Andrew Muir, Philip Raskin, Jay S. Skyler, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, Anette‐Gabriele Ziegler, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group - Diabetes Care 2023 cited by 96

  9. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

    Authors: Thomas Danne, Satish K. Garg, Anne L. Peters, John B. Buse, Chantal Mathieu, Jeremy Pettus, Charles M. Alexander, Tadej Battelino, Francisco Javier Ampudia‐Blasco, Bruce W. Bode, Bertrand Cariou, Kelly L. Close, Paresh Dandona, Sanjoy Dutta, Ele Ferrannini, Spiros Fourlanos, George Grunberger, Simon Heller, Robert R. Henry, Martin J. Kurian, Jake A. Kushner, Tal Oron, Christopher G. Parkin, Thomas R. Pieber, Helena W. Rodbard, Desmond Schatz, Jay S. Skyler, William V. Tamborlane, Koutaro Yokote, Moshe Phillip - Diabetes Care 2019 cited by 356

  10. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

    Authors: Michael J. Haller, Desmond Schatz, Jay S. Skyler, Jeffrey P. Krischer, Brian N. Bundy, Jessica Miller, Mark A. Atkinson, Dorothy J. Becker, David A. Baidal, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, Antoinette Moran, Henry Rodriguez, William E. Russell, Darrell M. Wilson, Carla J. Greenbaum, Type 1 Diabetes TrialNet ATG-GCSF Study Group, Carla J. Greenbaum, Mark A. Atkinson, David A. Baidal, M. Battaglia, Dorothy Becker, P. J. Bingley, Emanuele Bosi, Jan C. Buckner, Mark A. Clements, Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Mikael Knip, J. Krischer, Åke Lernmark, W. Moore, Antoinette Moran, Andrew J. Muir, J. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, W. J. Russell, Lisa M. Spain, Desmond Schatz, Jay M. Sosenko, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Mark S. Anderson, Peter A. Antinozzi, Christophe Benoıst, J.J. Blum, Kasia Bourcier, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, Catherine C. Cowie, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, L. Harrison, Bernhard J. Hering, Richard A. Insel, Sabine D. Jordan, Francine Kaufman, Tom Kay, Norma S. Kenyon, R. Klines, John M. Lachin, Ellen Leschek, Jeff Mahon, Jennifer B. Marks, Roshanak Monzavi, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, A. Pugliese, John A. Ridge, Bart O. Roep, Maria Grazia Roncarolo, Peter J. Savage, Olli Simell, R S Sherwin, Mark Siegelman, Jay S. Skyler, Andrea K. Steck, James W. Thomas, Massimo Trucco and 212 more - Diabetes Care 2018 cited by 180

  11. B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

    Authors: Mark D. Pescovitz, Carla J. Greenbaum, Brian N. Bundy, Dorothy J. Becker, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Jennifer B. Marks, Antoinette Moran, Philip Raskin, Henry Rodriguez, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler, the Type 1 Diabetes TrialNet Anti-CD20 Study Group - Diabetes Care 2013 cited by 282

  12. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

    Authors: Antoinette Moran, Brian N. Bundy, Dorothy Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Carla J. Greenbaum, Kevan C. Herold, Jennifer B. Marks, Philip Raskin, Srinath Sanda, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler, Linda Pickersgill, Eelco J.P. de Koning, Anette‐G. Ziegler, Bernhard O. Boehm, Klaus Badenhoop, Nanette C. Schloot, J. F. Bak, Paolo Pozzilli, Dı́dac Mauricio, Marc Y. Donath, Luís Castaño, Ana M. Wägner, H. H. Lervang, Hans Perrild, Thomas Mandrup‐Poulsen - The Lancet 2013 cited by 354

  13. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

    Authors: María J. Redondo, Susan Geyer, Andrea K. Steck, Seth A. Sharp, John M. Wentworth, Michael N. Weedon, Peter A. Antinozzi, Jay M. Sosenko, Mark A. Atkinson, Alberto Pugliese, Richard A. Oram, Type 1 Diabetes TrialNet Study Group, Peter A. Antinozzi, Mark A. Atkinson, Manuela Battaglia, Dorothy J. Becker, P. J. Bingley, Emanuele Bosi, Jan C. Buckner, Peter G. Colman, Peter A. Gottlieb, Kevan C. Herold, Richard A. Insel, Tom Kay, Mikael Knip, Jennifer B. Marks, Antoinette Moran, James L. Palmer, Mark Peakman, Louis H. Philipson, Alberto Pugliese, P. Raskin, Henry Rodriguez, Bart O. Roep, William E. Russell, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Christophe Benoıst, J.J. Blum, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, Bernhard J. Hering, Francine Kaufman, Ellen Leschek, J. Mahon, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, Maria Grazia Roncarolo, Olli Simell, Robert Sherwin, Mark Siegelman, Andrea K. Steck, James W. Thomas, Massimo Trucco, J. Richard Wagner, Carla J. Greenbaum, Katarzyna Bourcier, Richard A. Insel, Jeffrey P. Krischer, Ellen Leschek, Lisa Rafkin, Lisa M. Spain, Catherine C. Cowie, Mary A. Foulkes, Heidi Krause‐Steinrauf, John M. Lachin, Saúl Malozowski, John Peyman, J P Ridge, Peter J. Savage, Jay S. Skyler, Stephanie J. Zafonte, Norma S. Kenyon, Irene Santiago, Jay M. Sosenko, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, Brian N. Bundy, Cristina Burroughs, David Cuthbertson, Mary Deemer, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson and 1,520 more - Diabetes Care 2018 cited by 169

  14. Novel therapies with precision mechanisms for type 2 diabetes mellitus

    Authors: Leigh Perreault, Jay S. Skyler, Julio Rosenstock - Nature Reviews Endocrinology 2021 cited by 131

  15. COVID-19 and metabolic disease: mechanisms and clinical management

    Authors: Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Tkachuk Va, Alexander G. Markov, Hendrik Lehnert, Martin Hrabě de Angelis, Hannes Rietzsch, Roman N. Rodionov, Kamlesh Khunti, David Hopkins, Andreas L. Birkenfeld, Bernhard O. Boehm, Richard I. G. Holt, Jay S. Skyler, J. Hans DeVries, Éric Renard, Robert H. Eckel, K. G. M. M. Alberti, Bruno Geloneze, Juliana C.N. Chan, Jean Claude Mbanya, H C Onyegbutulem, Ambady Ramachandran, Abdul Basit, Mohamed Hassanein, Gavin A. Bewick, Giatgen A. Spinas, Felix Beuschlein, Rüdiger Landgraf, Francesco Rubino, Geltrude Mingrone, Stefan R. Bornstein - The Lancet Diabetes & Endocrinology 2021 cited by 250

  16. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

    Authors: Michael J. Haller, S. Alice Long, J. Lori Blanchfield, Desmond Schatz, Jay S. Skyler, Jeffrey P. Krischer, Brian N. Bundy, Susan Geyer, Megan Warnock, Jessica Miller, Mark A. Atkinson, Dorothy J. Becker, David A. Baidal, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, Antoinette Moran, Henry Rodriguez, William E. Russell, Darrell M. Wilson, Carla J. Greenbaum, Type 1 Diabetes TrialNet ATG-GCSF Study Group, Carla J. Greenbaum, Mark A. Atkinson, David A. Baidal, Manuela Battaglia, Dorothy J. Becker, P. J. Bingley, Emanuele Bosi, Jane H. Buckner, Mark A. Clements, Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter Gottlieb, Kevan C. Herold, Mikael Knip, Jeffrey P. Krischer, Åke Lernmark, Wayne D. Moore, Antoinette Moran, Andrew J. Muir, Jerry P. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, William E. Russell, Desmond A. Schatz, Jay M. Sosenko, Lisa M. Spain, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette G. Ziegler, Mark S. Anderson, Peter A. Antinozzi, Richard A. Insel, Thomas W. H. Kay, Jennifer B. Marks, Alberto Pugliese, Bart O. Roep, Jay S. Skyler, Jorma Toppari, Carla J. Greenbaum, Jeffrey P. Krischer, Ellen Leschek, Lisa Spain, Katarzyna Bourcier, Richard A. Insel, J P Ridge, Jay S. Skyler, Carla J. Greenbaum, Lisa Rafkin, Jay M. Sosenko, Jay S. Skyler, Irene Santiago, Jeffrey P. Krischer, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Ilma Asif, Jenna Bjellquist, Matthew Boonstra, Cristina Burroughs, Mario Cleves, David Cuthbertson, Meagan DeSalvatore, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Susan Geyer and 178 more - Diabetes 2019 cited by 131

  17. Fall in C-Peptide During First 2 Years From Diagnosis

    Authors: Carla J. Greenbaum, Craig A. Beam, David Boulware, Stephen E. Gitelman, Peter A. Gottlieb, Kevan C. Herold, John M. Lachin, Paula McGee, Jerry P. Palmer, Mark D. Pescovitz, Heidi Krause‐Steinrauf, Jay S. Skyler, Jay M. Sosenko, on behalf of the Type 1 Diabetes TrialNet Study Group - Diabetes 2012 cited by 320

  18. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

    Authors: Moshe Phillip, Peter Achenbach, Ananta Addala, Anastasia Albanese-O’Neill, Tadej Battelino, Kirstine J. Bell, Rachel Besser, Ezio Bonifacio, Helen M. Colhoun, Jennifer Couper, Maria E. Craig, Thomas Danne, Carine de Beaufort, Klemen Dovč, Kimberly A. Driscoll, Sanjoy Dutta, Osagie Ebekozien, Helena Elding Larsson, Daniel J. Feiten, Brigitte I. Frohnert, Robert A. Gabbay, Mary Gallagher, Carla J. Greenbaum, Kurt Griffin, William Hagopian, Michael J. Haller, Christel Hendrieckx, Emile Hendriks, Richard I. G. Holt, Lucille Hughes, Heba M. Ismail, Laura M. Jacobsen, Suzanne Bennett Johnson, Leslie E. Kolb, Olga Kordonouri, Karin Lange, Robert W. Lash, Åke Lernmark, Ingrid Libman, Markus Lundgren, David M. Maahs, M. Loredana Marcovecchio, Chantal Mathieu, Kellee M. Miller, Holly K. O’Donnell, Tal Oron, Shivajirao P. Patil, Rodica Pop‐Busui, Marian Rewers, Stephen S. Rich, Desmond Schatz, Rifka Schulman‐Rosenbaum, Kimber M. Simmons, Emily K. Sims, Jay S. Skyler, Laura Smith, Cate Speake, Andrea K. Steck, Nicholas Thomas, Ksenia N. Tonyushkina, Riitta Veijola, John M. Wentworth, Diane K. Wherrett, Jamie Wood, Anette‐Gabriele Ziegler, Linda A. DiMeglio - Diabetes Care 2024 cited by 68

  19. Practical recommendations for the management of diabetes in patients with COVID-19

    Authors: Stefan R. Bornstein, Francesco Rubino, Kamlesh Khunti, Geltrude Mingrone, David Hopkins, Andreas L. Birkenfeld, Bernhard O. Boehm, Stephanie A. Amiel, Richard I. G. Holt, Jay S. Skyler, J. Hans DeVries, Éric Renard, Robert H. Eckel, Paul Zimmet, K. G. M. M. Alberti, Josép Vidal, Bruno Geloneze, Juliana C.N. Chan, Linong Ji, Barbara Ludwig - The Lancet Diabetes & Endocrinology 2020 cited by 993

  20. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes

    Authors: Jeffrey P. Krischer, Desmond Schatz, Brian N. Bundy, Jay S. Skyler, Carla J. Greenbaum - JAMA 2017 cited by 203

  21. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

    Authors: Diane K. Wherrett, Brian N. Bundy, Dorothy J. Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jennifer B. Marks, Roshanak Monzavi, Antoinette Moran, Tihamer Orban, Jerry P. Palmer, Philip Raskin, Henry Rodriguez, Desmond Schatz, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler - The Lancet 2011 cited by 369

  22. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum

    Authors: William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter, Itamar Raz, Julio Rosenstock, Matthew C. Riddle - Diabetes Care 2017 cited by 369

  23. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

    Authors: Hiddo J.L. Heerspink, Andreas L. Birkenfeld, David Z.I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per‐Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill - Diabetes Research and Clinical Practice 2023 cited by 57

  24. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

    Authors: Jerry P. Palmer, G. Alexander Fleming, Carla J. Greenbaum, Kevan C. Herold, Lisa D. Jansa, Hubert Kolb, John M. Lachin, Kenneth S. Polonsky, Paolo Pozzilli, Jay S. Skyler, Michael W. Steffes - Diabetes 2004 cited by 484